Lexeo Therapeutics announces positive interim phase 1/2 data for LX2006 in Friedreich ataxia cardiomyopathy: New York Wednesday, April 9, 2025, 12:00 Hrs [IST] Lexeo Therapeutics, ...

Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on ...

The firm plans to use improvement in left ventricular mass index and increased frataxin protein expression after LX2006 treatment as co-primary endpoints.

Lexeo Therapeutics, Inc. ( ($LXEO) ) has shared an announcement. On April 7, 2025, Lexeo Therapeutics announced positive interim results from ...

Ataxia Treatment Market, trends, and advancements in neurological disorder treatments. Discover growth drivers, key players, and forecasts up to 2035 ...

This approval offers a meaningful option for eligible Canadians living with this life-altering and life-shortening disease 3 who have long faced limited treatment options. "Friedreich's ataxia ...

A West Annapolis family has turned two life-altering diagnoses into more than $1 million for research toward finding a cure ...

Lexeo Therapeutics (LXEO) announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia ...